S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Genprex Stock Price, News & Analysis (NASDAQ:GNPX)

$0.23
0.00 (0.00%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.23
$0.25
50-Day Range
$0.20
$0.37
52-Week Range
$0.19
$1.94
Volume
309,720 shs
Average Volume
181,848 shs
Market Capitalization
$13.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Genprex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,198.7% Upside
$3.00 Price Target
Short Interest
Healthy
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.49) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

226th out of 932 stocks

Pharmaceutical Preparations Industry

81st out of 431 stocks


GNPX stock logo

About Genprex Stock (NASDAQ:GNPX)

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock Price History

GNPX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Genprex to Present at BIO-Europe 2023
Genprex to Present at BIO-Europe 2023 Conference
Genprex Schedules, Hosts Virtual Key Opinion Leader Event
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Genprex to Present at Upcoming H.C. Wainwright Conference
See More Headlines
Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNPX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,198.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.46 per share

Miscellaneous

Free Float
52,576,000
Market Cap
$13.73 million
Optionable
Not Optionable
Beta
-0.10
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. John Rodney Varner (Age 66)
    Co-Founder, Chairman, President & CEO
    Comp: $886.97k
  • Mr. Ryan M. Confer M.S. (Age 41)
    Chief Financial Officer
    Comp: $606.57k
  • Ms. Catherine M. Vaczy Esq. (Age 62)
    Executive VP, General Counsel, Corporate Secretary & Chief Strategy Officer
    Comp: $704.93k
  • Mr. David M. Schloss
    Senior Vice President of Human Resources
  • Mr. Thomas C. Gallagher Esq.
    Senior Vice President of Intellectual Property & Licensing
  • Dr. Mark S. Berger M.D. (Age 68)
    Chief Medical Officer
  • Dr. Suzanne Thornton-Jones
    Senior Vice President of Regulatory Affairs & Quality
  • Dr. Jack A. Roth F.A.C.S.
    M.D., Chairman of Scientific & Medical Advisory Board














GNPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genprex stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNPX shares.
View GNPX analyst ratings
or view top-rated stocks.

What is Genprex's stock price target for 2024?

1 brokerages have issued 12-month price targets for Genprex's stock. Their GNPX share price targets range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,198.7% from the stock's current price.
View analysts price targets for GNPX
or view top-rated stocks among Wall Street analysts.

How have GNPX shares performed in 2023?

Genprex's stock was trading at $1.45 at the start of the year. Since then, GNPX stock has decreased by 84.1% and is now trading at $0.2310.
View the best growth stocks for 2023 here
.

Are investors shorting Genprex?

Genprex saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,340,000 shares, a drop of 18.3% from the October 31st total of 1,640,000 shares. Based on an average daily volume of 298,100 shares, the short-interest ratio is currently 4.5 days.
View Genprex's Short Interest
.

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our GNPX earnings forecast
.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), Advanced Micro Devices (AMD).

Who are Genprex's major shareholders?

Genprex's stock is owned by a number of institutional and retail investors. Top institutional investors include AMH Equity Ltd (1.37%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine M Vaczy and John Rodney Varner.
View institutional ownership trends
.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNPX) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -